Galmed director Nir Shmuel reports initial holdings

Galmed Pharmaceuticals Ltd. director Nir Shmuel filed an initial ownership report showing his equity position in the company.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. director Nir Shmuel filed an initial ownership report showing his equity position in the company. He directly holds 11,286 Ordinary Shares, stock options over 111 and 166 underlying Ordinary Shares with exercise prices of 558.0000 and 2080.8000, and several Restricted Share Unit (RSU) grants totaling thousands of units.

The RSUs vest over time, subject to his continued service, including one grant vesting on August 7, 2026, another in four equal installments on May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, and a third grant vesting from August 26, 2026 through August 26, 2028.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Nir Shmuel

Role Director

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Restricted Share Units	--	--	--
holding	Restricted Share Units	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 277 contracts (Direct); Ordinary Shares — 11,286 shares (Direct); Restricted Share Units — 25,208 shares (Direct)

Footnotes (3)

1. F1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.
2. F2. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.
3. F3. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Galmed Pharmaceuticals (GLMD) director Nir Shmuel report in this Form 3?

Nir Shmuel reports his initial equity holdings in Galmed Pharmaceuticals. He directly owns 11,286 Ordinary Shares, options over 277 underlying shares in total, and multiple RSU grants that vest over several future dates, all subject to continued service conditions.

How many Galmed Pharmaceuticals Ordinary Shares does Nir Shmuel directly hold?

He directly holds 11,286 Ordinary Shares of Galmed Pharmaceuticals. This figure reflects his reported ownership as of the Form 3 date and provides a baseline view of his direct equity stake as a company director, separate from options and RSU awards.

What stock options for Galmed Pharmaceuticals shares does Nir Shmuel hold?

He holds options to purchase Ordinary Shares with 111 underlying shares at an exercise price of 558.0000 and 166 underlying shares at 2080.8000. These options expire on July 15, 2031 and July 10, 2028, respectively, if not exercised earlier.

What are the key vesting terms of Nir Shmuel’s Galmed RSU awards?

One RSU grant vests on August 7, 2026, while another vests in four equal installments on May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027. A third grant vests between August 26, 2026 and August 26, 2028, all requiring continued service.

Does this Galmed Form 3 show any recent insider buying or selling by Nir Shmuel?

No specific buy or sell transactions are shown; the entries are labeled as holdings. The Form 3 provides a snapshot of his existing Ordinary Shares, options, and RSUs rather than documenting new open-market purchases or sales of Galmed stock.

Why is Nir Shmuel’s Form 3 important for Galmed Pharmaceuticals investors?

It establishes a clear record of the director’s starting equity stake in Galmed Pharmaceuticals. Investors can see his direct share ownership, option positions, and time-based RSU awards, which together indicate his exposure to the company’s long-term share performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 07:45 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nir Shmuel

(Last) (First) (Middle)

C/O MEITAR LAW OFFICES

16 ABBA HILLEL SILVER RD.

(Street)

RAMAT GAN 5250608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	11,286	D
Restricted Share Units	1,042(1)	D
Restricted Share Units	11,666(2)	D
Restricted Share Units	12,500(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares	07/15/2021	07/15/2031	Ordinary Shares	111	$558	D
Options to Purchase Ordinary Shares	07/10/2018	07/10/2028	Ordinary Shares	166	$2,080.8	D

Explanation of Responses:

1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.

2. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

3. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

	/s/ Shmuel Nir	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)